Combination of Venetoclax and Azacitidine in Patients with Treatment-Naive, High-Risk Myelodysplastic Syndromes with Responses Leading to Stem Cell Transplantation

被引：2

作者：

Garcia-Manero, Guillermo ^{[1
]}

Odenike, Olatoyosi ^{[2
,3
]}

Fleming, Shaun ^{[4
]}

Roboz, Gail J. ^{[5
,6
]}

Jacoby, Meagan ^{[7
]}

Cunningham, Ilona ^{[8
,9
]}

Kreuzer, Karl-Anton ^{[10
]}

Enjeti, Anoop K. ^{[11
]}

Baer, Maria R. ^{[12
]}

Cook, Rachel ^{[13
]}

Jurcic, Joseph ^{[14
]}

Ku, Grace ^{[15
]}

Zhou, Ying ^{[16
]}

Hoffman, David ^{[16
]}

Potluri, Jalaja ^{[16
]}

Garcia, Jacqueline S. ^{[17
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[2] Univ Chicago Med, Chicago, IL USA

[3] Ctr Comprehens Canc, Chicago, IL USA

[4] Australasian Leukaemia & Lymphoma Grp ALLG, Melbourne, Australia

[5] Weill Cornell Med, New York, NY USA

[6] New York Presbyterian Hosp, New York, NY USA

[7] Washington Univ, Sch Med, St Louis, MO USA

[8] Concord Hosp, Dept Haematol, Concord, NH USA

[9] Univ Sydney, Sydney, NSW, Australia

[10] Cologne Univ Hosp, Cologne, Germany

[11] Calvary Mater Hosp, Waratah, Australia

[12] Univ Maryland, Dept Med, Sch Med, Baltimore, MD USA

[13] Oregon Hlth & Sci Univ, Portland, OR USA

[14] Columbia Univ, Med Ctr, New York, NY USA

[15] Genentech Inc, San Francisco, CA USA

[16] AbbVie Inc, N Chicago, IL USA

[17] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA

来源：

关键词：

D O I：

10.1182/blood-2023-187102

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4